Metabolism Drugs Market Forecasts to 2030 – Global Analysis By Therapy Type (Substrate Reduction Therapy, Enzyme Replacement Therapy, Small Molecule Drugs and Other Therapy Types), Drug Class (Antihyperlipidemic Drugs, Antidiabetic Drugs and Other Drug Cl

Metabolism Drugs Market Forecasts to 2030 – Global Analysis By Therapy Type (Substrate Reduction Therapy, Enzyme Replacement Therapy, Small Molecule Drugs and Other Therapy Types), Drug Class (Antihyperlipidemic Drugs, Antidiabetic Drugs and Other Drug Classes), Distribution Channel, Application and By Geography

According to Stratistics MRC, the Global Metabolism Drugs Market is accounted for $17.45 billion in 2023 and is expected to reach $30.85 billion by 2030 growing at a CAGR of 8.4% during the forecast period. Metabolism drugs are medications designed to influence or regulate metabolic processes in the body. They are also known as metabolic modulators. They can have various benefits depending on the specific drug and the medical condition it is intended to treat. Metabolism drugs help the patient to improve cardiovascular health, enhance exercise performance, increase energy levels, reduce cholesterol levels and aids in weight management.

According to the World Health Organization (WHO), about 650 million people suffer from obesity in 2016 and is expected to increase more than four-fold times by 2030.

Market Dynamics:

Driver:

Rising prevalence of metabolic disorders

As the number of individuals diagnosed with metabolic disorders like diabetes, obesity, hyperlipidemia, and metabolic syndrome continues to rise, there is a larger patient population in need of treatment. Many metabolic disorders are chronic conditions that require ongoing treatment and management. The broad spectrum of metabolic disorders and the diverse range of drugs needed to treat them provide a wide market landscape. This increased demand for medications to manage these conditions directly supports the growth of the metabolism drugs market.

Restraint:

Limited patient populations

Metabolic disorders, especially rare or orphan diseases, often have a small patient population. This means that the potential market for drugs targeting these conditions is limited compared to more prevalent diseases. The small patient population may not generate enough revenue to justify the investment required for research, development, clinical trials, and marketing of a metabolism drug. The smaller market size can make it financially challenging for pharmaceutical companies to recoup the high costs of drug development. This can result in a lack of competitive options for patients.

Opportunity:

Growing focus on combination therapies

Combining drugs can result in synergistic effects, where the combined action of the drugs is greater than the sum of their individual effects. This can lead to improved clinical outcomes, allowing for better management of metabolic disorders. Metabolic disorders often involve complex physiological processes and may be influenced by multiple factors. Combination therapies allow for a more comprehensive approach to address these complexities, leading to more effective disease management. Thereby, their effectiveness, personalized medicines, expanded treatment options and minimization of side effects propels the market demand.

Threat:

High development costs

High development costs can hinder the metabolism drugs market as they can make pharmaceutical companies more risk-averse, leading them to focus on safer, more established drug development pathways rather than taking risks on innovative metabolism drugs. Also, in order to recoup their development costs, pharmaceutical companies may need to set higher prices for metabolism drugs. This can potentially limit access for patients and create challenges for healthcare systems in providing affordable treatments.

Covid-19 Impact

The Covid-19 pandemic has had varying impacts on the metabolism drugs market, depending on the specific drugs and the underlying conditions they treat. Due to lockdowns, restrictions, and concerns about visiting healthcare facilities, some individuals have delayed seeking medical attention for metabolic conditions. This lead to delayed diagnosis and treatment, potentially impacting the metabolism drugs market. On the other hand, the adoption of telemedicine and remote monitoring technologies have influenced how metabolic conditions were managed, potentially affecting prescription patterns for metabolism drugs. The market has been raised back in the post pandemic.

The small molecule drugs segment is expected to be the largest during the forecast period

The small molecule drugs segment is estimated to have a lucrative growth, due to their specific characteristics and benefits. They are designed to interact with specific molecular targets, such as enzymes, receptors, or signalling pathways, involved in metabolic processes. This allows for precise modulation of metabolic pathways, enabling the treatment of disorders like diabetes, hyperlipidemia, and obesity. Small molecule drugs are often less expensive to manufacture and can be more cost-effective for patients and healthcare systems.

The diabetes management segment is expected to have the highest CAGR during the forecast period

The diabetes management segment is anticipated to witness the highest CAGR growth during the forecast period. Metabolism drugs play a crucial role in diabetes management by helping to regulate blood sugar levels. They help to stabilize blood sugar levels, reducing the risk of hyperglycemia (high blood sugar) and its associated complications. It improves blood sugar control, reduces risk of complications, enhances quality of life and also customizes treatment plans which are thereby accelerating the segment growth.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period. Asia-Pacific countries, including China, India, Japan, and South Korea, are witnessing a rising prevalence of metabolic disorders such as diabetes, obesity, and cardiovascular diseases. This trend is driven by factors like sedentary lifestyles, dietary changes, and genetic predispositions. With economic growth and a rising middle-class population, many countries in the Asia-Pacific region have seen an increase in healthcare expenditure. Also, governments in various Asia-Pacific have been taking measures to address the growing burden of metabolic disorders.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period. Europe is a dynamic sector within the pharmaceutical industry. The metabolism drugs market in Europe is competitive, with both multinational pharmaceutical companies and local manufacturers playing significant roles. Companies like Novo Nordisk, Sanofi, AstraZeneca, and Eli Lilly have a strong presence in this market. Also, Europe has a well-established framework for orphan drug designation and approval, which includes certain rare metabolic disorders.

Key players in the market

Some of the key players profiled in the Metabolism Drugs Market include Novartis AG, Merck & Co Inc., Sanofi Genzyme, Amicus Therapeutics, AstraZeneca PLC, Horizon Pharma PLC, Shire PLC, Boehringer Ingelheim, BioMarin Pharmaceutical Inc., Takeda Pharmaceuticals, GlaxoSmithKline PLC, Fuji Yakuhin, Mitsubishi Tanabe Pharma, Kowa Company, LG Life Science, Kythera Labs and Eli Lilly.

Key Developments:

In October 2023, Novartis, a global leader in immuno-dermatology and rheumatology, announced that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS.2

In October 2023, Sanofi launched speciality care growth products Beyfortus® and ALTUVIIIO® for the protection of all infants against RSV. Sanofi's profitability has improved as a result of the portfolio restructuring with these products.

In April 2023, Eli Lilly launched the diabetes and weight loss drugs Ozempic and Wegovy. Participants had lost about 21% of their body weight, which was unprecedented. The medications come at a time when obesity is the most prevalent chronic condition, affecting an estimated 650 million adults globally.

Therapy Types Covered:
• Substrate Reduction Therapy
• Enzyme Replacement Therapy
• Small Molecule Drugs
• Other Therapy Types

Drug Classes Covered:
• Antihyperlipidemic Drugs
• Antidiabetic Drugs
• Other Drug Classes

Distribution Channels Covered:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Applications Covered:
• Diabetes Management
• Obesity Treatment
• Hyperlipidemia Management
• Thyroid Disorders
• Metabolic Syndrome
• Rare Metabolic Disorders
• Other Applications

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements